1. Home
  2. BHV vs MRKR Comparison

BHV vs MRKR Comparison

Compare BHV & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackRock Virginia Municipal Bond Trust

BHV

BlackRock Virginia Municipal Bond Trust

N/A

Current Price

$11.25

Market Cap

20.1M

Sector

Finance

ML Signal

N/A

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

N/A

Current Price

$1.04

Market Cap

19.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BHV
MRKR
Founded
N/A
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.1M
19.5M
IPO Year
2002
2010

Fundamental Metrics

Financial Performance
Metric
BHV
MRKR
Price
$11.25
$1.04
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $7.87
AVG Volume (30 Days)
6.5K
★ 64.1K
Earning Date
01-01-0001
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 33.61
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$19.61
Revenue Next Year
N/A
$375.85
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$10.04
$0.84
52 Week High
$15.15
$2.46

Technical Indicators

Market Signals
Indicator
BHV
MRKR
Relative Strength Index (RSI) 41.13 37.42
Support Level $10.53 $1.08
Resistance Level $12.99 $1.31
Average True Range (ATR) 0.82 0.07
MACD -0.12 -0.01
Stochastic Oscillator 25.81 4.17

Price Performance

Historical Comparison
BHV
MRKR

About BHV BlackRock Virginia Municipal Bond Trust

Blackrock Virginia Municipal Bond Trust is a perpetual closed-end municipal bond fund. Its objective is to provide current income exempt from regular Federal income taxes and Virginia personal income taxes.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

Share on Social Networks: